BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, January 2, 2026
Home » Authors » Omar Ford

Omar Ford

Articles

ARTICLES

MDD's Diagnostics Extra

July 24, 2015
By Omar Ford

When an angel isn't enough: MDI stands in the gap between funding, getting devices to market

July 24, 2015
By Omar Ford

St. Jude, Thoratec show a lot of Heart in transaction: St. Jude shows it has 'heart' with proposed $3.4B Thoratec acquisition

July 23, 2015
By Omar Ford
St. Jude Medical (NYSE:STJ) (St. Paul, Minn.) said that it has agreed to acquire Thoratec (NASDAQ:THOR) (Pleasanton, Calif.) for $63.50 per share in a cash transaction valued at about $3.4 billion.
Read More

EHRS not ready for Prime Time: Physicians point out challenges to EHR adoption during town hall meeting

July 22, 2015
By Omar Ford

iDesign provides Map of the eye: Abbott's iDesign provides a map of the eye for Lasik procedures

July 21, 2015
By Omar Ford

NewCo on the Go: Rivanna Medical gains clearance for smart phone-sized ultrasound

July 20, 2015
By Omar Ford

MDD's Diagnostics Extra

July 17, 2015
By Omar Ford

2Q15 Report: Med-tech investing, IPOs rule funding landscape for 2Q15

July 17, 2015
By Omar Ford

Personalized medicine gains momentum: Medtronic products may bridge gaps leading to personalized lung treatments

July 17, 2015
By Omar Ford
The goalpost for a health care system solely focused on personalized medicine always gets closer when the FDA clears devices and technologies like Medtronic's (NYS:MDT) GenCut biopsy system. The tool works with the company's superDimension navigation system – a device that's often called a GPS tracking system for the lung. Medtronic reported launching the device, earlier this week.
Read More

Bioabsorbable stent movement heating up: BVS market heats up as top players with different solutions vie for U.S. approval

July 16, 2015
By Omar Ford
The race for med-tech companies to get a bioabsorbable stent (BVS) on the U.S. market for coronary intervention procedures is quickly heating up. Abbott Vascular (Santa Clara, Calif.), a division of Abbott (NYSE: ABT) (Abbott Park, Ill.), is pulling away from other competitors in the space and has developed a BVS that can be fully dissolved within the body.
Read More
View All Articles by Omar Ford

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 31, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 31, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing